US 12054758

I'll research US 12054758 directly, using the patent text you've supplied as the authoritative baseline and searching for current USPTO/PTAB/CAFC records.

Let me pull the claim set and the current PTAB/CAFC status.

Now let me retrieve the actual claim text for the '758 patent.

US 12,054,758 — verification and summary

I searched specifically for patent number 12,054,758 (not similar numbers). Every hit I retrieved that touches this number refers to the same document — US 12,054,758 B2, application 18/066,960 — so I have reasonable confidence the records below all describe the single patent you asked about. I did not find any Court of Appeals for the Federal Circuit docket naming this patent (see "CAFC status" below), and I flag where I am inferring rather than reading authoritative text.

---

1. Bibliographic data

Abstract (as it appears verbatim in the patent record): "Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof." (Confirmed against the Unified Patents patent page and the Onscope record; the abstract text is not in the abbreviated definitional excerpt of the specification I was given, which was truncated before the claims.)

---

2. What the patent is about, in one paragraph

Human PH20 is a neutral-active, sperm-derived hyaluronidase used as a "spreading"/permeability agent to help therapeutic drugs (antibodies, insulin, etc.) disperse and be absorbed — most famously as the basis of Halozyme's rHuPH20 (Hylenex®) and its ENHANZE® drug-delivery business. Native PH20 loses activity under stress conditions relevant to formulation and storage: elevated temperature (≥ ~30 °C, e.g. body temperature or pump/continuous-infusion conditions), agitation, low/no salt, and the presence of denaturing excipients such as phenolic preservatives (phenol, m-cresol). This patent describes engineered PH20 variants carrying defined amino-acid substitutions (referenced to mature soluble PH20, SEQ ID NO:3) that retain hyaluronidase activity while showing improved stability under one or more of those conditions, plus pharmaceutical compositions containing them (optionally with a preservative and/or a co-administered therapeutic agent such as a fast-acting insulin) and methods of use.

---

3. Plain-language overview of the independent claims

Important caveat: the authoritative text I was given is truncated before the claims, and I was unable to retrieve a verbatim, source-verified claim set. The following is reconstructed from the PGR petition and the PTAB institution decision for PGR2025-00030, which quote and characterize the claims directly. I flag each inference.

• Claim 1 (independent — the principal composition-of-matter claim). Covers a modified (variant) PH20 hyaluronidase polypeptide defined structurally by two things: (a) it is at least 91% identical to any of SEQ ID NOs: 3, 7, or 32–66 (these are mature full-length human PH20 and its soluble C-terminally truncated forms, roughly 430–465 residues), and (b) it contains an amino-acid modification at the position corresponding to position 317 of SEQ ID NO:3. The petition's analysis of the claim genus indicates six alternative substitutions are permitted at position 317 (Ala, Ile, Lys, Met, Gln, Arg). "Corresponding position" is determined by alignment. In practice this is a genus claim — the petition characterizes it as capturing on the order of 10¹¹² distinct polypeptides (≤474 residues, up to ~42 substitutions, six options at 317). There is a live construction dispute over whether claim 1 requires the polypeptide to have hyaluronidase activity: the patent owner argued it does not; at institution the Board adopted the patent's own express definition of "modified PH20 polypeptide," which does require "some hyaluronidase activity." That is a preliminary construction, not a final one.

• Claim 2 (independent or dependent — uncertain). Appears to be a narrower version of the same genus: the petition's tables list it with a maximum of ~23 total changes (versus ~42 for claim 1) and the same position-317 options. Because it carries its own genus parameters rather than pointing to claim 1's, I suspect it is a further independent claim, but I could not verify whether it depends from claim 1. Flagging as unverified.

• Independent composition/method claims (likely within claims 24–30). The petition states that the claims following the polypeptide claims "define pharmaceutical compositions and methods of use," and that these claims "employ the genus definition used in claim 1" without further narrowing the polypeptide genus — i.e. a pharmaceutical composition comprising a claim-1-type modified PH20 (optionally with a preservative and/or a second therapeutic agent such as a fast-acting insulin), and methods of treatment or of delivering a therapeutic agent using that genus. The exact independent-claim numbering and wording is not verified; the dependent claims in this block add features such as N-linked glycosylation at residues corresponding to N200, N333, and N358, and conjugation (e.g. PEGylation, Fc/multimerization domains).

Statutory disclaimer: Before the Board's institution decision, Halozyme disclaimed claims 3–5 and 31–40 of the '758 patent. Those claims are therefore treated as never having existed; the live claim set is claims 1–2 and 6–30. This matters to your "independent claim" question — at least one independent claim asserted at issuance has been surrendered.

---

4. Post-grant and litigation posture (as reflected in my search results)

• PTAB post-grant review: PGR2025-00030, Merck Sharp & Dohme LLC v. Halozyme, Inc., patent 12,054,758 (application 18/066,960). Petition filed February 4, 2025; petitioner is Merck Sharp & Dohme (MSD). Grounds: (i) claims 1–40 lack adequate written description under 35 U.S.C. § 112; (ii) claims 1–40 are not enabled under § 112; (iii) claims 1–2, 5–6, 8, and 10–40 are obvious under § 103 over the '429 patent (US 7,767,429), Chao, and skilled-artisan knowledge. Merck also alleged PGR eligibility on the ground that at least one claim is not entitled to a pre-March 16, 2013 effective filing date (i.e., the 13/694,731 application is asserted not to provide § 112 support for the claims). The USPTO Director denied Halozyme's discretionary-denial requests in August–September 2025 and referred the institution decisions to the panel; the Board instituted trial on PGR2025-00030 (reported in the October 2025 institution-decision decision/venue commentary).
• District court: Halozyme, Inc. sued MSD in the U.S. District Court for the District of New Jersey — case 2:25-cv-03179 (filed April 24, 2025) — asserting this patent among roughly fifteen Halozyme MDASE/PH20 patents against MSD's subcutaneous pembrolizumab (Keytruda Qlex™ / berahyaluronidase alfa). Halozyme is seeking damages and an injunction.
• CAFC status: no 2026 Federal Circuit docket found. I searched for a Federal Circuit appeal naming 12,054,758 and found none. This is consistent with the procedural posture: an appeal to the Federal Circuit under 35 U.S.C. § 141/319 would lie only from a final written decision (or, in limited circumstances, from an institution decision on mandamus). Given institution in roughly October 2025, the statutory final written decision deadline under § 326(a)(11) would fall around October 2026 — so as of the timeframe of my search results, PGR2025-00030 was still pending with no FWD and therefore no ripe CAFC appeal. I cannot rule out a mandamus petition or an appeal docketed after my search coverage; treat this as "not found," not "confirmed nonexistent."

One caution about dating: your prompt gives the current date as April 26, 2026, while my operating parameters specify September 28, 2026. My search results include material dated into October 2025 but nothing later, so please treat the procedural status above as accurate as of that coverage window rather than as of either stated "today."

---

5. Points where I am not certain

1. Verbatim claim text. I could not source the exact wording of claims 1–30 from an authoritative full-text claim listing; the overview above is reconstructed from the PGR petition's and institution decision's quotations and characterizations. Independent/predecessor relationships among claims 2, 24, and 27–30 are inferred.
2. Dates. Issue date (Aug 5 vs Aug 6, 2024), filing date (Dec 14 vs Dec 15, 2022), and priority date (Dec 29 vs Dec 30, 2011) differ by one day between the Unified Patents portal and Google Patents. I have reported both rather than "correcting" one into the other.
3. Legal effect of the disclaimer. I report the disclaimer of claims 3–5 and 31–40 as stated by the PTAB/venue commentary; I have not independently reviewed the statutory disclaimer filing under 37 C.F.R. § 1.321.
4. Effective priority date. The patent's face value priority claim is December 30, 2011, but this is actively disputed in PGR2025-00030. Do not treat the 2011 date as settled for any claim.

I'll search for litigation records specifically involving US 12,054,758, updating the earlier findings.

Let me target the district court docket, the PTAB case, and any Federal Circuit appeals.

Let me check for any Federal Circuit appeal and the current status of the New Jersey case.

Litigation involving US Patent 12,054,758

I searched specifically for the number 12,054,758 (and the issued number "12054758"). Every result that touches this number refers to the same document — US 12,054,758 B2, application 18/066,960, "PH20 Polypeptide Variants, Formulations and Uses Thereof," Halozyme — so I have good confidence the records below concern the correct patent.

Bottom line: US 12,054,758 is involved in exactly one dispute family, all between Halozyme and Merck Sharp & Dohme (MSD), over MSD's subcutaneous pembrolizumab (Keytruda Qlex™/Keytruda SC™, which uses Alteogen's berahyaluronidase alfa / ALT‑B4). That dispute has two US fora touching the '758 patent: a district-court infringement action and a PTAB post-grant review. I found no US litigation naming the '758 patent against any other party.

(A note on scope: the broader Halozyme/MSD war also includes German, UK, and Dutch proceedings, but those are based on European Halozyme patents, not on US 12,054,758. I list them separately below so they aren't miscounted as '758 cases.)

---

1. District-court patent infringement action

Note on one date discrepancy: a Pearce IP / Lexology write-up states Halozyme "sued MSD in the US on 24 April 2024." The federal docket and Halozyme's own PTAB mandatory notices both put the complaint at April 24, 2025, consistent with the March 2025 licensing-demand reports. The "2024" appears to be a typo in that secondary source; the docket controls.

---

2. PTAB post-grant review (AIA trial, not district-court litigation)

This is the most active "litigation" front for the '758 patent.

Context worth noting: this proceeding sits inside a coordinated MSD campaign against 14–15 Halozyme MDASE patents. As of September 2026, PTAB had invalidated the challenged claims of several sibling patents (US 11,952,600; 12,018,298; 12,152,262; 12,123,035; 12,110,520) on written-description/enablement grounds, and MSD had also filed three IPRs (IPR2026-00312/-00313/-00314 against 10,865,400; 11,041,149; 11,066,656). Those outcomes don't bind PGR2025-00030, but they signal the § 112 theory MSD is pressing against the '758 claims as well.

---

3. Federal Circuit (CAFC) status

No Federal Circuit appeal involving US 12,054,758 was found. This is consistent with the posture: no final written decision has issued in PGR2025-00030, so the ordinary § 141/§ 319 appeal path is not yet ripe, and the New Jersey case has not reached judgment. I was unable to complete a final, exhaustive CAFC/PACER check within my search budget, so treat this as "not found," not "confirmed nonexistent." If a party moved for Director Review and then sought mandamus, or if a FWD issued after my coverage, an appeal docket could exist that I did not surface.

---

4. Foreign proceedings — not on US 12,054,758 (flagged to avoid conflation)

The same commercial dispute includes non-US actions, but these assert European Halozyme patents, not US 12,054,758, so they should not be counted as '758 litigation:

• Germany: In December 2025 the Munich Regional Court granted Halozyme a preliminary injunction barring MSD from distributing/offering Keytruda SC in Germany (based on a European Halozyme patent; reportedly still in place as of mid‑2026). Alteogen states it is not a party.
• United Kingdom: Halozyme's infringement counterclaim on EP 2 797 622 was found "speculative and weak," with the Patents Court awarding MSD indemnity costs (decision reported May–June 2026); Halozyme had agreed to surrender the UK designation.
• Netherlands: In July 2026 the District Court of The Hague dismissed Halozyme's provisional-injunction application against Keytruda SC for Denmark/Sweden.

---

5. Summary table

No other litigation involving US 12,054,758 is known to me — no ITC action, no other district-court defendant, no other PTAB petition against the '758 patent beyond PGR2025-00030.

---

Points of uncertainty

1. Verbatim claim text of the '758 patent is not source-verified in my materials (the authoritative text I was given is truncated before the claims); claim descriptions are taken from the PGR petition, the Board's institution materials, and the ex parte case summary.
2. PGR2025-00030 timing — I confirmed institution on Oct 16, 2025 and that it was still pending per a Sept 9, 2026 update, but I could not retrieve a later docket entry; a FWD may have issued after my coverage.
3. CAFC check incomplete due to tool-step limits (see §3).
4. Effective priority date — the '758 patent's face-value 2011 priority is actively contested in the PGR; do not treat it as settled.

Consistency check with the earlier generated section: the institution date (Oct 16, 2025), the petition date (Feb 4, 2025), the disclaimer of claims 3–5 and 31–40, the ~10¹¹²-claim genus, and the NJ case number all match. The one item I would correct/flag is the "April 24, 2024" filing date that appears in one secondary source — the docket shows April 24, 2025.

I'll start by reconciling the structured ODP block against the proceeding already documented in the prior section, then verify current status via search.

Now let me check for 2026 developments — oral hearing, settlement/motion to terminate, or an FWD.

Proceedings overview

Reconciliation flag first: the structured "PTAB proceedings on file" block in my prompt says the USPTO ODP returns no AIA trial proceedings for US 12,054,758. That block is wrong — public PTAB records show one PGR on this patent, and it is live. Per your instruction I flagged it rather than defaulting to "no PTAB activity." The canonical count is therefore one proceeding: PGR2025-00030 — instituted, active, no final written decision yet, no claims held unpatentable, no settlement.

Bottom-line defensive posture for a defendant today: the patent is fully intact on paper and simultaneously under its strongest validity attack. Claims 3–5 and 31–40 were surrendered by Halozyme's own statutory disclaimer before institution, but no claim of the '758 patent has been canceled by the Board. At the same time, the Board's institution decision on this patent tracks § 112(a) reasoning that the same panel has now used to invalidate the sibling MDASE patents in PGR2025-00003, -00004 and -00006. That is a meaningful predictive signal, not a holding. Do not brief the '758 as if claim 1 were dead — it is not.

---

PGR2025-00030 — Merck Sharp & Dohme LLC v. Halozyme, Inc.

• Type: Post-Grant Review (35 U.S.C. §§ 321–329)
• Filed: 2025-02-04
• Patent: US 12,054,758 B2 (application 18/066,960)
• Status: Pending – Instituted (Unified Patents portal status string: "Pending - Instituted"; institution date 2025-10-16). No FWD, no termination order, no appeal.
• Real parties-in-interest: Petitioner names Merck Sharp & Dohme LLC only; Patent Owner names Halozyme, Inc. and Halozyme Therapeutics, Inc.
• Judge panel: Jeffrey N. Fredman, Susan L. C. Mitchell, Cynthia M. Hardman, and Michael A. Valek, Administrative Patent Judges (same panel hears the consolidated MDASE PGR family). Source: Docket Alarm case page for PGR2025-00030; panel also recited in the Board's 2026 order captioned "PGR2025-00003 (11,952,600 B2) et al."
• Petition grounds (challenged claims 1–40):
  1. § 112(a) — written description and enablement, claims 1–40. The claims cover 10⁵⁹ to 10¹¹² modified PH20 polypeptides; every working example is a single-substitution PH20₁₋₄₄₇ mutant, while the claims reach multiply-substituted variants and C-terminally truncated forms the specification itself teaches may be inactive. Cited Amgen v. Sanofi, 598 U.S. 594 (2023) and Idenix v. Gilead, 941 F.3d 1149 (Fed. Cir. 2019). Petitioner also argued the "research plan" is prophetic and iterative (up to 41 rounds).
  2. § 103 — claims 1–2, 5–6, 8, and 10–40 over US 7,767,429 (patent owner's own patent) in view of Chao (2007 Biochemistry). The theory: the claims capture at least one obvious species, L317Q in PH20₁₋₄₄₇; the '429 patent teaches single substitutions in non-essential regions "do not substantially alter biological activity," and Chao supplies the structure/alignment to identify position 317 as non-essential and Q as the most prevalent residue there.
• PGR eligibility (threshold): Petitioner asserted the '758 is PGR-eligible because at least one claim lacks § 112(a) support in U.S. App. No. 13/694,731 (the only pre-2023-03-16 application in the § 120 chain, which issued as US 9,447,401), i.e., no valid Inguran/Collegium benefit claim to the 2011–2012 priority dates. The effective priority date is therefore still contested.
• Patent owner's disclaimer: Before institution, Halozyme statutorily disclaimed claims 3–5 and 31–40. Those claims are treated as never having existed. (Disclaimed claim numbers confirmed by Venable's BiologicsHQ coverage, citing EX2003.)
• Institution decision: Instituted 2025-10-16. Verbatim from the decision: "we determine that the information presented shows that it is more likely than not that Petitioner would prevail in establishing unpatentability of claims 1, 2, and 6-30 of the '758 patent, and therefore, we grant post-grant review for the reasons articulated below."
  • Review the institution decision here: https://biologicshq.com/wp-content/uploads/2025/10/PTAB-PGR2025-00030-Institution-Decision.pdf
  • Claim-level scope of institution: claims 1, 2, and 6–30. Claims 16 and 24, 27–30 (the composition/method claims) are within that instituted set; claims 3–5 and 31–40 are outside it because of the disclaimer.
  • Key preliminary construction: the panel declined Halozyme's argument that the claims do not require hyaluronidase activity, holding that the '758's own express definition of "modified PH20 polypeptide" imports an activity requirement. Halozyme had argued the claims are "structural, not functional" (Prelim. Resp. 46, citing In re Entresto, 125 F.4th 1098). The Board's construction was preliminary and is not dispositive.
  • Not verified: whether the § 103 ground was also instituted, or denied institution. The decision's institution sentence is stated at the level of claims, not grounds. Venable's reporting on the sibling PGRs (PGR2025-00017, -00033, -00039) states the Board declined the obviousness grounds in those cases — do not assume that holding carries over to -00030 without checking the decision text.
• Discretionary denial: The Director denied Halozyme's discretionary-denial requests (including the § 325(d) argument that Chao is cumulative to Stern and a Fintiv argument) in the August–September 2025 window and referred the institution decisions to the panels. Petitioner's reply also notes Halozyme has "cancelled 66 such claims across 9 patents" in response to the same § 112(a) theories.
• Final Written Decision: None issued as of this analysis. Statutory deadline under 35 U.S.C. § 326(a)(11) is one year from institution, i.e., on or about 2026-10-16, extendable up to six months for good cause. Given today's date, an FWD is imminent but I found no authoritative record of one for this patent.
  • Important disambiguation: a 2026-09-02 report describes an FWD holding claims 1, 2, 6–15, and 17–30 unpatentable in a fifth MDASE PGR. That claim list excludes claim 16, which was instituted in PGR2025-00030. Because the institution dates line up better with PGR2025-00017 (instituted 2025-09-08, FWD due ~2026-09-08) than with PGR2025-00030 (instituted 2025-10-16, FWD due ~2026-10-16), I cannot attribute that September 2026 FWD to the '758 patent, and I do not. Verify the patent number on the face of the decision before relying on it.
• Settlement / termination: No settlement. Halozyme instead moved to terminate all fourteen of Merck's instituted PGRs (including -00030) on 2026-02-16, for MSD's alleged failure to name Merck & Co., Inc. ("MCI") as a real party-in-interest — the same RPI theory that was in play after Corning. Key procedural events:
  • 2026-02-12 — Board conference call on the RPI motion.
  • 2026-03-02 — hearing in the first four PGRs; the RPI motion was argued. The Board thereafter authorized a Petitioner declaration on the RPI issue (due 2026-03-12) and cross-examination (transcript due 2026-03-27), plus five-page supplemental briefs (due 2026-04-02).
  • The Board denied Halozyme's motion to terminate, and Halozyme has sought Director Review of that denial, arguing that in PGR2025-00087 the Director denied institution on the same RPI reasoning. I could not verify the denial date or the Director Review disposition. Note this is one joint motion across fourteen proceedings; nothing in what I retrieved suggests a case-specific outcome for the '758.
• Appeal: No Federal Circuit appeal found. None is ripe — an appeal under 35 U.S.C. § 141/319 lies only from an FWD. Halozyme's Director Review request (if granted and adverse) is a separate track. Treat CAFC status as "none found," not "confirmed none."
• Related litigation: Halozyme, Inc. v. Merck Sharp & Dohme Corp., 2:25-cv-03179 (D.N.J.), filed 2025-04-24, asserting the '758 among ~15 MDASE patents against subcutaneous pembrolizumab (Keytruda Qlex™, pembrolizumab + berahyaluronidase alfa-pmph). The '758 is named as a related matter in the institution decision itself. There is no stay on this record; Merck argued at the discretionary-denial stage that a stay is likely and that a D.N.J. trial would not occur until ~May 2030.
• Defensive value: This is the most valuable defensive signal you have and the least reliable one. The Board has already found more-likely-than-not that claims 1, 2 and 6–30 are invalid under § 112(a), and the same panel has since invalidated three sibling MDASE patents on the same reasoning. But there is no judgment against any claim of the '758, so an infringement theory built on claim 1 today is legitimate, not sanction-bait — it is a bet on a pending FWD.

---

Strategic summary

Canceled vs. sustained vs. untested. Nothing is canceled by the Board. Disclaimed (surrendered, treated as never existing): claims 3–5 and 31–40. Under review (instituted 2025-10-16): claims 1, 2, and 6–30 — that is claims 1, 2, 6–15, 16, 17–30. Untested: none — the live claim set is entirely within the instituted scope. If you are drafting a defense around a specific claim, note that claims 3–5 / 31–40 no longer exist, so any invalidity contention, invalidity contentions chart, or invalidity position keyed to those numbers is a nullity and should be withdrawn.

Estoppel landscape. Two distinct issues.

• PGR estoppel, 35 U.S.C. § 325(e)(2): binds Merck Sharp & Dohme LLC and its privies, and only after an FWD, from raising in a civil action or ITC proceeding any ground they raised or reasonably could have raised. It does not bind you.
• Your own access to the Board: IPR is statutorily barred while PGR2025-00030 is pending. Under § 311(c), an IPR petition may not be filed until the later of 9 months after grant or the date of termination of the instituted PGR. The PGR window itself closed 2025-05-06 (9 months after the 2024-08-06 grant). So a new party's only Board route now is a § 42.122(b) joinder request — and the joinder window (one month from institution) closed on or about 2025-11-16. Practically: you must wait for the FWD, then file an IPR limited to §§ 102/103 grounds, and you lose § 112 challenges entirely — the very ground on which this patent is currently being attacked. That asymmetry is the single most important strategic fact here. Separately, § 315(b)'s one-year bar runs from service of a complaint on you, so a stale demand letter alone does not start the clock.

Pattern signals. Merck filed 15 PGRs against 15 related Halozyme MDASE patents (14 of which are jointly captioned), between November 2024 and June 2025; all 14 identified in the institution decision were instituted. This is a coordinated portfolio attack, not a one-off. Consistent rulings: PGR2025-00003 ('600, FWD 2026-05-12, claims held unpatentable; Halozyme had disclaimed claims 5–7), PGR2025-00006 ('262), and PGR2025-00004 ('298, FWD 2026-06-08) — three FWDs by June 2026, all adverse to Halozyme, all on written description/enablement, all with the Board invalidating the remaining claims after Halozyme disclaimed some. Halozyme is fighting aggressively on procedure (joint motion to terminate across 14 PGRs; Director Review requests; a parallel UK action where it offered to revoke EP 622 on 2026-03-31; a German preliminary injunction it won on 2025-12-04 over EP 2 797 622). No defensive aggregator is in the chain — the petitioner is the accused infringer itself, which means the estoppel and RPI fights are commercial, not aggregator-driven. Merck's own § 112 briefing leans hard on the fact that the accused ALT-B4 enzyme has "more than 30 changes from Hylenex®," so the "we made active mutants" narrative is contested on the merits too.

---

Recommended next steps

1. Get the FWD the day it issues (~2026-10-16 statutory date). It will be docketed at PTAB E2E: https://ptacts.uspto.gov/ptacts/ — the PGR2025-00030 docket page is also mirrored at https://www.docketalarm.com/cases/PTAB/PGR2025-00030/Merck_Sharp_%26_Dohme_LLC_v._Halozyme_Inc/. Quote the disposition claim-by-claim; do not assume the September 2026 FWD you may see in news coverage belongs to this patent.
2. Watch the Director Review track. Halozyme has asked the Director to review the denial of its RPI-based motion to terminate across the fourteen PGRs. If Director Review were granted and the proceedings terminated, the § 311(c) bar lifts and an IPR becomes immediately available — a materially different posture. Monitor Docket Alarm's PGR2025-00030 page and the USPTO Director Review page.
3. Do not build a case on the disclaimer. If a demand letter or complaint asserts claims 3–5 or 31–40, respond that those claims were statutorily disclaimed before institution and have no legal existence.
4. Preserve § 112 arguments outside the Board. Because an IPR cannot reach written description or enablement, any § 112(a)/§ 112(b) defense must be developed for the district court or ITC now, informed by the Board's preliminary construction that "modified PH20 polypeptide" requires hyaluronidase activity. Also prepare for Halozyme to argue prosecution-history estoppel or claim-construction consistency across the '758 and its siblings (18/759,577; 18/922,889; 18/069,651; 18/340,786; 19/071,005; 19/071,055; 19/075,092; 19/071,264; 19/071,345; US 12,195,773; US 12,264,345), which the institution decision lists as related.
5. If you are served, diarize § 315(b) immediately and evaluate a § 42.122(b) joinder request — but understand the joinder window for PGR2025-00030 has already closed.

Unverified points I want to be explicit about: (a) whether the § 103 ground was instituted or denied in PGR2025-00030; (b) the exact date and reasoning of the Board's denial of the RPI motion as it applies to this specific proceeding; (c) whether a second statutory disclaimer removed claim 16 from the instituted set; (d) the total family-wide FWD tally — I confirmed FWDs in PGR2025-00003, -00004, and -00006, and separately saw a report of a fifth MDASE FWD, but I did not verify every proceeding number.

I'll research the assignment/ownership record for US 12,054,758, cross-referencing USPTO assignment data, PTAB/litigation records, and SEC filings.

Ownership reconstruction — US 12,054,758 B2

Scope note up front. I identified three recorded post-issuance/pre-issuance assignment events for this patent, but I was unable to retrieve reel/frame numbers or the correspondent of record for any of them from live sources. I am not going to invent those fields. The material below states precisely what was found, where, and what still requires an Assignment Center pull to verify.

---

Inventors

Unusual-pattern check — one flag, but a benign one. Three inventors (Wei, Shepard, Zhao) appear on the 2022-12-19 assignor filings as a group to Halozyme Therapeutics, Inc., while Shepard was handled as a separate assignment directly to Halozyme, Inc. Treating one inventor's paper separately is the classic fingerprint of a left-the-company inventor from whom a confirmatory/ratifying assignment had to be collected years after the fact. H. Michael Shepard is widely reported as a Halozyme founder and former president/CEO, and he is listed at an Oregon address rather than at the San Diego campus. I did not verify his exact departure date in the sources retrieved, so I flag this as consistent with a departed-inventor confirmatory assignment rather than proven.

That pattern — rather than "all inventors left within 12 months" — is the opposite of the portfolio-fire-sale tell you asked me to look for. The inventors' rights were being swept back in, not sold out.

---

Original assignee

Halozyme, Inc. (San Diego, California) is the assignee named on the face of the issued patent, and it remains the owner of record today.

• Product embodying the claims — yes, unequivocally. Halozyme commercializes rHuPH20, the recombinant human hyaluronidase that is the subject of this patent family. It is the active ingredient in the approved product HYLENEX® and the backbone of the ENHANZE® drug-delivery platform, under which Halozyme licenses to Roche, Takeda/Baxalta, Pfizer, Janssen, AbbVie, Lilly, BMS, argenx and others (Halozyme FY2024 Form 10-K, per stocklight.com mirror; Nasdaq: HALO, CIK 0001159036).
• Primary line of business: commercial-stage biopharmaceutical / drug-delivery licensing. Halozyme is a royalty-and-product revenue operating company, not a licensing-only shell.
• Corporate structure (matters for chain-of-title): Halozyme, Inc. is the operating subsidiary; Halozyme Therapeutics, Inc. is the Nasdaq-listed parent. Halozyme's own 10-Q describes "substantially all of the assets of the Company and our subsidiary, Halozyme, Inc." — i.e. the patent-holding entity sits below the public parent. This exactly explains why the recorded chain runs inventors → Halozyme Therapeutics, Inc. → Halozyme, Inc. rather than to an outside party.
• Current status: operating, profitable, and affirmatively litigating (not in bankruptcy, not dissolved, not acquired). A historical encumbrance is worth noting: the 2015 term loan with Oxford Finance / Silicon Valley Bank was secured by Halozyme, Inc.'s assets, but the Nov 2019 8-K confirms those amounts were repaid in full from the convertible-note proceeds. No security agreement appears in the legal-events feed for this patent.

---

Assignment timeline

⚠️ Reel/frame and correspondent fields are unresolved. Google Patents legal events discloses the existence, parties, and recording date of these recordings but not the reel/frame or the correspondent of record; my web queries did not surface the underlying Assignment Center records. The entries below are therefore verified as to parties and date, unverified as to reel/frame and correspondent. Do not cite a reel/frame for this patent until it is pulled from Assignment Center.

All three recordings below are dated 2022-12-19 — four days after application 18/066,960 was filed on 2022-12-15 (continuity per the patent's own Definitions section).

• Execution date not disclosed / recorded 2022-12-19 — Reel not retrieved

  • Conveyance: Assignment
  • Assignor: CONNOR, ROBERT JAMES; WEI, GE; ZHAO, Qiping
  • Assignee: HALOZYME THERAPEUTICS, INC.
  • Correspondent: not retrieved — recurrence check impossible; this is the single most important open field (see Verdict caveat)
  • Context: internal corporate-chain step — inventors' rights into the listed parent, routine rights-perfection for the family.

• Execution date not disclosed / recorded 2022-12-19 — Reel not retrieved

  • Conveyance: Assignment
  • Assignor: HALOZYME THERAPEUTICS, INC.
  • Assignee: HALOZYME, INC.
  • Correspondent: not retrieved
  • Context: internal reorganization — parent-to-operating-subsidiary transfer within the same corporate group; no change in ultimate beneficial ownership.

• Execution date not disclosed / recorded 2022-12-19 — Reel not retrieved

  • Conveyance: Assignment
  • Assignor: SHEPARD, H. MICHAEL
  • Assignee: HALOZYME, INC.
  • Correspondent: not retrieved
  • Context: confirmatory assignment from a long-absent founder-inventor, routed directly to the operating subsidiary. Consistent with (not proof of) an employment/invention-assignment cleanup.

No fourth assignment exists on the record. Nothing has moved this patent off Halozyme, Inc. There is no LLC, no IP-holdings vehicle, no Marathon/Acacia/IV-style transferee anywhere in the chain.

Verification links: USPTO Assignment Center and the Assignment Search mirror — search by patent number 12054758 and/or application 18/066960; the three 2022-12-19 records should be captured in a single pull with their reel/frame and correspondent. Cross-reference the legal-events feed at patents.google.com/patent/US12054758/en.

---

Timeline diagram

timeline
    title Ownership of US 12054758
    2011 : Provisionals 61631313 and 61796208 filed
    2012 : Parent app 13694731 filed
    2022 : Continuation 18066960 filed Dec 15
         : Three assignments recorded Dec 19
         : Inventors to Halozyme Therapeutics
         : Parent to subsidiary Halozyme Inc
         : Shepard confirmatory assignment
    2024 : US 12054758 issues Aug 6
    2025 : Halozyme sues Merck in D NJ Apr 24
         : Merck files PGR2025-00030 Feb 4
         : Board institutes PGR Oct 16

---

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No assignment to any entity with an "IP / Patents / Licensing / Holdings / Ventures" suffix exists in the record. The chain terminates at Halozyme, Inc., a product-revenue operating subsidiary of a Nasdaq-listed company. The only "transfer to a different name" is the 2022-12-19 HALOZYME THERAPEUTICS, INC. → HALOZYME, INC. parent-to-subsidiary step — an internal group move, not a shell transfer.

2. Known asserter in the chain — not present. Neither Halozyme, Inc. nor Halozyme Therapeutics, Inc. appears on any of the enumerated NPE lists (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Unified Patents classifies the patent owner as "Halozyme Inc — Operating Company" on its PGR2025-00030 record (portal.unifiedpatents.com). The adverse petitioner is the far larger operating company: Merck Sharp & Dohme LLC, classified "Large Operating Company."

3. Repeat correspondent across the chain — unclear; cannot be scored. I could not retrieve the correspondent of record for any of the three 2022-12-19 recordings. Recurrence is the whole signal, and a single unverified appearance would not be a finding anyway. This is the one field I would insist on completing before closing the file — if the same outside counsel appears as correspondent on the Halozyme recordings across the ~15-patent MDASE family, that is normal in-house/outside-counsel prosecution practice and still not an NPE indicator; it would only become interesting if the same name also recurs on unrelated LLC-owned patents. No such link was found.

4. Cascading transfers — not present. Three recordings share a single date (2022-12-19) and a single corporate group. There is no chain of successive unrelated LLCs, no common registered-agent address, no sub-24-month daisy chain. The clustering is a one-day chain-of-title perfection tied to the 2022-12-15 continuation filing, not a cascade.

5. Pre-litigation transfer — not present. The last recorded assignment (2022-12-19) sits roughly 28 months before the first infringement suit naming this patent — Halozyme, Inc. v. Merck Sharp & Dohme LLC, D.N.J. 2:25-cv-03179, filed 2025-04-24. That is far outside the 6-month window. There is no last-minute transfer arranged to set venue or manufacture standing.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 proceeding involving Halozyme, Inc. or Halozyme Therapeutics, Inc. The company is profitable and reported record revenue (ENHANZE royalties plus its auto-injector business). No assignment to any purchaser-in-bankruptcy appears.

7. Privateering — not present. Privateering requires transfer to an NPE that asserts on the operating company's behalf. Here Halozyme itself is the named plaintiff, asserting its own patents against a competitor's product (MSD's subcutaneous pembrolizumab with Alteogen's berahyaluronidase alfa). Halozyme did offer MSD a licence in March 2025 before suing (per the WSJ report as relayed by Pearce IP / Lexology) — that is ordinary commercial licensing behaviour by a patent owner, not privateering. Notably, no assignment of this patent to any Alteogen- or MSD-related vehicle appears either.

8. Defensive aggregator — not present. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. (Unified Patents appears here only as a data provider indexing the PGR, not as an assignee.)

---

Verdict

Operating-company assertion.

The chain never leaves the Halozyme corporate group: inventors → Halozyme Therapeutics, Inc. → Halozyme, Inc., plus a separate 2022-12-19 confirmatory assignment from founder-inventor H. Michael Shepard, all recorded on one day four days after the 2022-12-15 continuation filing (USPTO Assignment Center, patent 12054758; Google Patents legal events). The owner is a commercial-stage operating company that ships rHuPH20/HYLENEX® and licenses ENHANZE®, and it is suing a direct competitor — MSD — over MSD's own subcutaneous Keytruda® product in D.N.J. 2:25-cv-03179 (filed 2025-04-24), while defending PGR2025-00030 before the PTAB (instituted 2025-10-16). Zero of the eight NPE signals is present; one (repeat correspondent) is merely unscored for lack of data. Verify the chain and capture the missing reel/frame and correspondent fields at assignmentcenter.uspto.gov searching number 12054758.

---

Cross-reference flags against the earlier sections

1. Contradiction carried forward, not resolved: priority date is 2011-12-29 (Unified Patents) vs 2011-12-30 (Google Patents); grant 2024-08-05 vs 2024-08-06; filing 2022-12-14 vs 2022-12-15. My searches reproduce the same one-day split. Do not silently normalize.
2. New procedural fact not in the prior summary: a Federal-Written-Decision PDF captioned Merck v. Halozyme, PGR2025-00017, is indexed as "Unpatentable" and concerns US 12,110,520 — a sibling patent in this family, not the '758 patent. I mention it only as context; it is not a finding about US 12,054,758, whose own PGR2025-00030 was still listed as "Pending – Instituted" in the Unified Patents case list. If that FWD timing is right, the family has begun to take validity damage, which bears on strategy but not on ownership.
3. Real-party-interest point worth carrying into the earlier "Issues" section: the PTAB record lists both Halozyme, Inc. and Halozyme Therapeutics, Inc. as real parties-in-interest — consistent with the parent/subsidiary structure established by the 2022-12-19 recordings and the SEC filings.

I'll research the prior-art citations for US 12,054,758 specifically. Let me run several targeted searches in parallel.

Let me get the actual front-page "References Cited" for this specific patent.

Bottom line up front

The single most important finding: on the record I could actually verify, US 12,054,758 has no reference asserted against it under 35 U.S.C. § 102 (anticipation). Every prior-art reference I could source in this patent's post-grant record is deployed by the petitioner under § 103 (obviousness). The two references that matter most are:

1. U.S. Patent No. 7,767,429 ('429 patent) — used as the primary structural/motivation reference; and
2. Chao et al., Biochemistry 46:6911–6920 (2007) — used as the secondary reference for identifying "non-essential regions" of PH20 by alignment.

I also have to flag a scope limit honestly: I could not retrieve the verbatim, face-of-patent "References Cited" list (the examiner-cited U.S. patent documents and non-patent literature printed on the front page of US 12,054,758). The authoritative full text supplied to me is truncated before the claims and contains no citation list, and my searches returned the family/forward-citation data rather than the § 56 disclosure. See § D below for exactly what this means and how to close the gap.

---

A. Prior art I could verify in the US 12,054,758 record

Source is the Merck (MSD) PGR2025-00030 petition against the '758 patent (exhibit table reproduced at http://www.pearceip.law/wp-content/uploads/2025/03/MSD-v-Halozyme-IPR-Petitions-Filed-Nov-2024-to-Feb-2025.pdf), corroborated by the PTAB institution decision (https://biologicshq.com/wp-content/uploads/2025/10/PTAB-PGR2025-00030-Institution-Decision.pdf).

---

B. Why § 102 anticipation is essentially not on the table here

Claim 1 of the '758 patent is a genus claim, and the verified records frame it as: a modified PH20 polypeptide comprising (i) an unmodified PH20 consisting of SEQ ID NO: 3, 7, or 32–66, at ≥ 91% identity, and (ii) a replacement at the position corresponding to residue 317 (SEQ ID NO:3 numbering) selected from A, I, K, M, Q, R (the Korean analyst table at http://stock.mk.co.kr/uploads/20250310/1741562979_8d6fd4c272cb90588eea.pdf and the petition both render claim 1 this way).

For § 102 anticipation of a genus claim, a single reference must disclose a species falling within the genus (or the genus with sufficient specificity that a skilled artisan would "at once envisage" the members). Neither verified reference does that:

• The '429 patent is asserted only to motivate and expressly claim generically substitutions in non-essential regions — not to disclose a specific residue-317 mutant. That is the classic § 103 posture, and it is precisely why the petition briefs the "L317Q" species as an obvious species (see the passage: "claims 1‑2, 5‑6, 8, and 10‑40 are unpatentable because each captures at least one obvious PH20₁₋₄₄₇ mutant … leucine at position 317 to glutamine").
• Chao is a structural biology paper on Hyal‑1 and cannot disclose the claimed modified PH20.

The claims that would be at risk if a § 102 reference existed disclosing an L317A/I/K/M/Q/R single-substitution PH20: claims 1 and 2 (the independent polypeptides) and every dependent claim that adds only features inherent in such a variant (e.g. glycosylation at positions corresponding to N200/N333/N358). Claims 24–30 (compositions/methods) would fall for the same reason, since they were asserted to "employ the genus definition used in claim 1" without narrowing it.

---

C. Points where I am inferring, not reading

1. Exhibit numbering is proceeding-specific. "EX1005 = US 7,767,429" and "EX1006 = Chao" come from the PGR2025-00030 exhibit table. The Stern/Arming/Zhang passages I found are quoted from a Patent Owner brief in a different PGR (it self-identifies as discussing PGR2025-00042 and the '773 patent). Do not carry those exhibit numbers across proceedings without re-verifying.
2. Ground-by-ground institution for '758 is unconfirmed. I have institution of PGR2025-00030 (reported instituted Oct. 10/16, 2025, per https://trial.medpath.com/zh/news/merck-faces-patent-challenge-over-keytruda-qlex-as-ptab-institutes-seven-post-grant-reviews and the Venable BiologicsHQ post). What I do not have is the operative text of the '758 institution decision telling us which grounds (all of § 112 and § 103, or a subset) were instituted. For the sibling patents ('520/'652/'185) Venable reports the Board instituted on § 112 but declined obviousness. Do not assume the same outcome for '758.
3. "WO 01/3087 ('WO087')" appears in the petition's recitation of the '731 application's priority chain. This identifier is ambiguous/possibly garbled and I am not auto-correcting it. It is not prior art regardless.
4. Provisional date ordering discrepancy. The petition text as I retrieved it states "61/631,313, filed November 1, 2012 and 61/796,208, filed December 30, 2011," whereas the patent's own Definitions section states the reverse (61/631,313 = Dec. 30, 2011; 61/796,208 = Nov. 1, 2012). This looks like an OCR/transcription artifact, but per your instruction I am reporting both rather than silently reconciling them.

---

D. What the task asked for that I could not deliver (and how to get it)

You asked me to "look at each patent citation for 12054758." The literal list of references cited on the face of US 12,054,758 — i.e., the examiner/applicant citations under 37 C.F.R. § 1.56 that appear in the "References Cited" box on the front page and in the IFW — is not present in the authoritative text I was given, and none of my searches surfaced it (they returned family members and forward citations instead, e.g. US 6,858,736 listing "US12054758B2" among documents citing it — that is a forward citation and is irrelevant as prior art). Similarly, the parent US 10,865,400's front-page list that I partially retrieved begins with old formulation/dosage-form patents (US 3,536,809; 3,598,123; 3,630,200 …), which suggests the family's cited-art list is broad and largely directed to drug-delivery/formulation art rather than PH20 variant art — but I have not verified that for the '758 patent itself.

To close this gap authoritatively you need one of:

• USPTO Patent Center / IFW for application 18/066,960 ("References Cited" and the "PTOL‑892"/form PTO‑1449), or
• the front page of the granted patent PDF (Google Patents → "Download PDF"), or
• PTAB Ex. 1001 in PGR2025-00030 (the '758 patent as filed), whose front page the petition's exhibit table at ptacts.uspto.gov/ptacts/public-informations/petitions/ should reproduce.

I did not have live USPTO PAIR/Patent Center access in this session, so I am not going to invent a citation list.

---

E. Contradictions / cross-checks against the earlier-generated sections

• Consistent: bibliographic data, continuity chain, position-317 claim scope (A, I, K, M, Q, R), PGR2025-00030/Merck, D.N.J. 2:25‑cv‑03179, and the disclaimer of claims 3–5 and 31–40 of the '758 patent (confirmed by Lexology/Venable: "claims 3-5 and 31-40 of the '758 patent").
• To reconcile: the earlier section states the § 103 ground runs over "the '429 patent … Chao, and skilled-artisan knowledge," which matches what I found. It is worth adding explicitly that this is an obviousness ground, not an anticipation ground — your current question invites a § 102 framing that the record does not support.
• Date caution: your prompt's "current date" (April 26, 2026) and my operating parameters (Sept. 28, 2026) differ. My search coverage runs through ~October 2025. Under § 326(a)(11), a final written decision in PGR2025-00030 would be due roughly October 2026; I found no Federal Circuit appeal and no FWD naming 12,054,758. Treat that as "not found," not "confirmed nonexistent."

---

F. Bottom line for your prior-art question

For US 12,054,758, the relevant prior art, as actually asserted, is:

• U.S. 7,767,429 (issued 2010) — § 103 primary reference; no verified § 102 anticipation.
• Chao et al. 2007 — § 103 secondary reference; no § 102 application.
• Stern, Arming, Zhang — § 103/cumulativeness references (citations unverified).

No reference in the verified record anticipates claims 1–2 or 6–30 under § 102; the attack is written-description/enablement (§ 112) plus obviousness (§ 103). If you want, I can attempt to pull the verbatim front-page "References Cited" and the full institution-decision grounds on a follow-up pass with targeted queries at Patent Center/PTAB.

I'll research the prior art cited in the PGR2025-00030 petition and related Halozyme PH20 art, then build the obviousness analysis.

Let me pull the specific claim language and the PGR2025-00030 institution decision, plus check for any final written decision.

Obviousness Analysis — U.S. Patent No. 12,054,758 (35 U.S.C. § 103)

Prepared: April 26, 2026
Basis: The prior art of record in the challenge to this patent — namely the grounds pleaded in Merck Sharp & Dohme LLC v. Halozyme, Inc., PGR2025-00030 — i.e., U.S. Patent No. 7,767,429 ("the '429 patent," EX1005), Chao et al., Biochemistry 46:6911-6920 (2007) (EX1006), and the knowledge of a person of ordinary skill in the art ("POSA"). I also address combinations with additional art of record or art considered during prosecution (Stern et al.; Frost, Expert Opin. Drug Deliv. 4:427-440 (2007); Bookbinder et al.; Lin et al.; Morrison; the multi-dose/preservative formulation art).

⚠️ Caveats up front. (i) The authoritative claim text I could verify is limited to claim 1 (quoted verbatim below from the PGR2025-00030 institution decision, citing Ex. 1001, 303:2-26) and the types of dependent claims; I have not verified the verbatim text or numbering of claims 2-30. (ii) As of the prior sections of this analysis, PGR2025-00030 had been instituted, but the sibling institution decisions (PGR2025-00017, -00024, -00042, -00052) each declined to institute on the § 103 ground, reasoning that "there must be some reason to select a species from the genus." I flag below where that reasoning likely carries over. (iii) I found no final written decision in PGR2025-00030 in my coverage.

---

1. The claim at issue

Claim 1 is the sole independent claim. Verbatim:

"1. A modified PH20 polypeptide, comprising one or more amino acid modifications in an unmodified PH20 polypeptide, wherein:
the unmodified PH20 polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7 and 32-66;
amino acid modifications are selected from the group consisting of amino acid replacements(s), deletion(s), and/or insertion(s);
the modified PH20 polypeptide comprises an amino acid replacement at a position corresponding to residue 317, with reference to amino acid positions set forth in SEQ ID NO:3;
the replacement at the position corresponding to residue 317 is selected from the group consisting of A, I, K, M, Q, and R;
corresponding amino acid positions are identified by alignment of the PH20 polypeptide with the polypeptide having the amino acid sequence of SEQ ID NO:[3]; and
the modified PH20 polypeptide has at least 91% sequence identity to the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 7 and 32-66."

Two structural features drive the entire § 103 analysis:

1. Claim 1 is a single-position claim. Everything it requires beyond the starting sequence collapses to: at least one modification, and a replacement to A, I, K, M, Q, or R at position 317. Claims that additionally require a functional property (increased stability, increased activity, solubility) are claims 3-5 and their dependents — and claims 3-5 were statutorily disclaimed by Halozyme before institution.
2. Claim 1 is an enormous genus. Dr. Park calculated 10⁵⁹-10¹¹² distinct polypeptides (Ex. 1004 ¶169; institution decision at 8). But claims are evaluated as a whole; a genus claim is invalid under § 103 where the art renders an embodiment within the genus obvious, unless the claim as a whole contains a limitation that saves it.

Live claim set: 1-2 and 6-30 (claims 3-5 and 31-40 disclaimed). The pleaded § 103 ground covered claims 1-2, 5-6, 8, and 10-40 — not claims 3, 4, 7, and 9 (the increased-stability/increased-activity claims). That omission is itself an implicit concession that the functional claims are not obvious over the art.

Statutory regime. The '758 patent is PGR-eligible (at least one claim is alleged not to be entitled to the pre-AIA March 16, 2013 effective filing date, because the '731 application is said not to provide § 112(a) support). As to the present art, the answer is the same under either regime: the '429 patent granted August 3, 2010 — more than one year before even the earliest claimed priority date (December 30, 2011) — and Chao published in 2007. Both are § 102(b) art under pre-AIA law and § 102(a)(1) art under the AIA.

---

2. Level of ordinary skill

A POSA in 2011 would hold an advanced degree (Ph.D. or M.D.) in biochemistry, molecular biology, protein engineering, or a related field, with several years of experience in recombinant protein expression, enzyme engineering, and pharmaceutical formulation of biologics. Critically, the POSA would be routinely familiar with multiple-sequence alignment, homology modeling, and rational/site-directed mutagenesis as standard protein-engineering tools, and with the practice of formulating and preserving therapeutic proteins.

---

3. Scope and content of the prior art

A. U.S. Patent No. 7,767,429 ('429) — the primary reference

The '429 patent is the patentee's own earlier patent (Halozyme), filed 2003 and granted 2010. It teaches:

• Soluble PH20₁₋₄₄₇: a C-terminally truncated, GPI-anchor-less human PH20 that is soluble, neutral-active, and glycosylated; the patent states that PH20₁₋₄₄₇ "omits the C-terminal residues containing the GPI anchor sequence and is thus soluble."
• The express design instruction: "Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity." This is the single most important sentence in the record: it is the patentee's own pre-2011 statement that a POSA would predict retention of biological activity for a substitution placed in a non-essential region of PH20₁₋₄₄₇.
• Claims to modified PH20: the '429 claims cover hyaluronidase glycoproteins that "contain[] amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477 … 36-483," i.e., the patentee claimed a genus of substituted soluble PH20 proteins without ever providing a single worked example of a substitution — relying entirely on that predictability statement.
• Downstream features: glycosylation at N-linked sites; modification with polymers (PEG or dextran); pharmaceutical compositions (1-5000 U/mL); co-formulation with a pharmaceutically active agent (chemotherapeutic agents, antibodies, etc.); subcutaneous administration; and uses in treating hyaluronan-associated disease and increasing delivery of therapeutic agents.

The '429 thus supplies both (a) the starting molecule (SEQ ID NO:3 / PH20₁₋₄₄₇) and (b) the motivation and the POSA-recognized expectation of success for single substitutions in non-essential regions.

B. Chao et al. (2007) — the structural/alignment reference

Chao reported the experimentally determined crystal structure of human HYAL1 and a structure-based alignment of the five human hyaluronidases (HYAL1-4 and PH20). It disclosed: invariant conserved positions; the three catalytic residues; conserved disulfide-forming cysteines; conserved N-glycosylation sites; predicted secondary-structure elements (e.g., the β-sheet N-terminal region and the α-helices); and a "novel, EGF-like domain" in the C-terminal region of human hyaluronidases, mapped to PH20 positions 337-409. Because Chao's alignment exposes which positions vary among homologs — the operational definition of a "non-essential" region in the '429's instruction — it supplies the rational-design bridge from the '429's generic teaching to a specific location in PH20.

Notably, Chao's Figure 3 places position 317 within the α8 helix of PH20, a segment bounded on the alignment by the conserved residues C316 and L327.

C. Stern et al. (2008), The Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action

Substantially cumulative to Chao in the respects relied upon: it aligns the same five human hyaluronidases, marks the same conserved residues (C316 and L327), and reproduces the same variable segments. Its significance here is defensive: it forecloses the "Chao is a new reference" and § 325(d) arguments by showing the same alignment teachings were on the Examiner's desk.

D. Frost (2007), Expert Opin. Drug Deliv. 4:427-440

Reviews rHuPH20 as an "enabling platform" for subcutaneous drug and fluid administration, and (as the patent itself acknowledges) the field understood that rHuPH20 "rapidly loses activity in the presence of preservatives … likely due to unfolding." This reference supplies the market/design incentive motive — a stable PH20 is needed for preserved, multi-dose, and pump/co-formulation products.

E. Formulation/preservative and conjugation art

The glycoprotein-formulation arts (multi-dose insulin, antibody, and other biologics products preserved with phenol and m-cresol; PEGylation of enzymes, including hyaluronidases per Bookbinder et al., J. Control. Release 114:230-241 (2006)) supply the elements of any composition/conjugate claims.

F. Lin et al. and Morrison (prosecution art)

The prosecution record reflects a rejection of a claim encompassing an L317A substitution as obvious over Lin et al. (human and monkey PH20 sequences) in view of Morrison (alanine scanning to probe residue function), the Examiner reasoning that it would have been obvious "to modify the PH20 polypeptide with an alanine anywhere along the protein sequence." ⚠️ I have been unable to verify that this exchange occurred in the '758 file history specifically (the excerpt I retrieved is from a related petition and may concern a sibling patent whose claim 1 was amended to delete alanine); but claim 1 of the '758 nevertheless retains A at position 317, so the rationale would be available on its face.

---

4. The primary § 103 combination: '429 + Chao (+ POSA knowledge)

4.1 Element-by-element mapping to claim 1

Result: the single-substitution species L317Q in PH20₁₋₄₄₇ (and equally L317A, L317I, L317K, L317M, L317R) falls within claim 1.

4.2 Why a POSA would have been motivated to combine — the express KSR rationales

1. Express teaching, suggestion, or motivation in the art (KSR prong G). The '429 directs the POSA to make "single amino acid substitutions in non-essential regions" of PH20₁₋₄₄₇ and claims the resulting proteins. Chao tells the POSA where the non-essential regions are. The combination requires no leap: it is the direct implementation of the patentee's own instruction using a publicly available map.
2. Known technique applied to a known molecule, with predictable results (KSR prongs B/C/D). Multiple-sequence alignment to locate variable (non-essential) positions and site-directed mutagenesis to change them were routine, well-understood techniques by 2011. Applying an accepted method to a known protein "ready for improvement" is the paradigm of predictable variation.
3. Design incentive and market forces (KSR prong F). The '429 already positioned rHuPH20 as a subcutaneous-enhancement platform. The need for PH20 variants that survive the conditions of commercial use — preservation in multi-dose vials, storage, and co-administration with insulin or antibodies (Frost 2007) — supplied a concrete reason to generate and test single-substitution variants.
4. "Obvious to try" among a finite, identified set of solutions (KSR prong E). The POSA is not choosing blindly: Chao delimits the variable regions, and the homology data identify a small, finite set of amino acids observed to occur at the position corresponding to 317 — with glutamine the single most frequent. Selecting Q is among the most predictable choices available.
5. Reasonable expectation of success. This is where the '758 patent's own family is most damaging. The '429 states that single substitutions in non-essential regions "do not substantially alter biological activity," and the patentee obtained claims over that genus without any working example of a substitution, thereby representing to the Office that the expectation of retained activity was sound. The POSA would additionally have expected retention because position 317 is distant from the catalytic site, the conserved cysteines, and the N-glycosylation sites that Chao identified as essential.

---

5. Alternative and secondary combinations

---

6. Dependent claims

• Post-translational modification / glycosylation claims (N-acetylglucosamine at N residues corresponding to N200, N333, N358 of SEQ ID NO:3): the '429 teaches that human PH20 must be glycosylated for activity and that CHO expression of PH20₁₋₄₄₇ yields a 61 kDa glycoprotein with six N-linked sites. Expressing a claimed variant in CHO is routine and yields the recited glycosylation. In re Vaeck / In re Wright-type reasoning: a product-by-process-like feature that inevitably results from the disclosed production method is obvious.
• Conjugation claims (PEG, dextran, multimerization domain/Fc): taught or suggested by the '429 (claim 9-10: "modified with a polymer … PEG or dextran") and Bookbinder.
• Pharmaceutical composition claims (pharmaceutically acceptable excipient; preservative; optional second therapeutic agent): the '429 expressly claims pharmaceutical compositions of the soluble PH20 at 1-5000 U/mL with a carrier and a pharmaceutically active agent; combination with a preservative and an insulin is a predictable formulation choice.
• Method-of-treatment / delivery-enhancement claims (treating a hyaluronan-associated disease; increasing delivery of a therapeutic agent; subcutaneous administration; administering before the second agent): the '429 discloses each purpose, route, and sequencing.

---

7. What would defeat the ground — and my assessment

The patent owner's strongest argument, and the one that prevailed at institution in the sibling proceedings, is:

Tolerance is not a positive reason to make a substitution. Knauf Insulation, Inc. v. Rockwool Int'l A/S, 788 F. App'x 728, 733 (Fed. Cir. 2019) ("It is not enough, even after KSR, … there must be some reason to select a species from the genus."). Dr. Park identified ~379 variable positions; the art's generic teaching that substitutions may be tolerated at any of them is not a reason to select position 317.

Related arguments the patent owner has deployed:

1. Neither the '429 nor Chao names position 317. True — but the combination does not require naming a position; it requires that the claimed invention as a whole would have been obvious. The counter is that Chao's alignment plus the homology data (Q = consensus at the corresponding position) supply the specific selection, not mere generic disclosure.
2. No reasonable expectation of retained activity. Halozyme argues that the effect of any substitution in PH20 was unpredictable. This is substantially undercut by the patentee's own '429 representation and by its '429 claims, which were obtained on that very prediction — a classic case for using the patentee's statements against it.
3. Secondary considerations / nexus. The '758 specification reports that L317Q showed increased activity, but (a) claims 3-4 (the stability/activity claims) are disclaimed, (b) the position-317 stability data (L317A/I/K/R) were mixed and no data existed for L317Q, and (c) the claims cover 10⁵⁹-10¹¹² species, most of which the patent owner concedes may be inactive — so any showing for one mutant is not commensurate with the claim scope (In re Hiniker; In re Kao nexus requirement).
4. Teaching away / structural significance. Chao notes the Hyal-EGF domain (PH20 337-409) is "closely associated" with the catalytic domain; the position-317 α8 segment is outside it (bounded by C316/L327), so this argument has limited purchase for the 317 claims — though it may support a broader argument that the C-terminal region is structurally sensitive.

My assessment: On this record, the § 103 ground against claim 1 is legally sound in structure — it relies on an express teaching in the patentee's own prior patent plus a routine, well-supported selection step — and it is materially stronger than the analogous grounds the Board declined in the sibling cases (e.g., PGR2025-00024 at position 307, PGR2025-00042 at position 309, PGR2025-00052 at position 313). The distinguishing facts here are: (i) glutamine at the position corresponding to 317 is the most prevalent residue in the homologous set (not merely "tolerated"), (ii) it appears in 2 of 5 human hyaluronidases in Chao's own Figure 3, and (iii) it has a helix propensity matching Chao's α8 assignment. Those are positive selection reasons, not tolerance alone. Whether that distinction is enough to survive the Board's Knauf skepticism is genuinely uncertain, and I would not predict the outcome confidently.

Most probable posture: institution of PGR2025-00030 appears to rest primarily on the § 112 written-description and enablement grounds (as in the sibling cases), with the § 103 ground being the harder sell. If the claims are cancelled on § 112, the § 103 question may never be reached on the merits.

---

8. Residual uncertainties

1. Verbatim dependent-claim text (claims 2, 6-30) is unverified; the mapping in § 6 describes claim types as reported in the petitions and institution decisions, and numbering across the Halozyme family is not consistent.
2. Whether the Board instituted on the § 103 ground in PGR2025-00030 specifically — I infer it did not, based on the identical reasoning articulated in the sibling institution decisions, but I have not read the '758 institution decision's § 103 section end-to-end.
3. The prosecution-history rejection over Lin/Morrison may belong to a sibling patent's file history rather than the '758's; treat as probative but unverified.
4. No final written decision in PGR2025-00030 was located within my search coverage; the § 326(a)(11) deadline (±1 year from the ~October 2025 institution) would fall around October 2026.
5. Secondary-consideration evidence (Halozyme's commercial success, multi-dose formulation need, industry praise) has not been developed in the record I can see; a robust nexus showing tied to a narrow claim could alter the calculus, but not for the genus of claim 1.